Ranked #1,507 of 8,699 institutional investors
EcoR1 Capital, LLC
San Francisco, CA
$2.03B
US stock portfolio at live prices · today +$25.6M (+1.28%)
Market closed. Prices as of Nov 20, 8:11 AM ET
- Value at quarter end (Q3 2026)
- $2.03B
- Change from Q2 2026
- +$17.5M (+0.87%)
- Positions
- 29 · 8 new, 5 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $218M of stock. $92.4M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesZYME 30.4%ANAB 18.4%CGON 7.55%ETON 7.46%TRAX 6.95%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ZYME Zymeworks Inc. | 22,970,388 | $617M | 30.4% | Unchanged |
| ANAB AnaptysBio, Inc. | 7,880,094 | $374M | 18.4% | Unchanged |
| CGON CG Oncology, Inc. | 1,871,892 | $153M | 7.55% | Added +25% |
| ETON Eton Pharmaceuticals, Inc. | 2,470,920 | $152M | 7.46% | Added +14% |
| TRAX First Tracks Biotherapeutics, Inc. | 3,174,519 | $141M | 6.95% | Unchanged |
| AKTS Aktis Oncology, Inc. | 4,824,469 | $79.1M | 3.90% | Unchanged |
| ANRO Alto Neuroscience Inc | 2,232,000 | $59.2M | 2.91% | New |
| LKFT Lakefront Biotherapeutics NV | 1,667,119 | $55.7M | 2.74% | Unchanged |
| ERAS Erasca, Inc. | 2,950,000 | $41.9M | 2.07% | Added +794% |
| ATTO Attovia Therapeutics, Inc. | 2,024,010 | $31.5M | 1.55% | New |
| NGNE Neurogene Inc. | 1,271,342 | $29.2M | 1.44% | Unchanged |
| FULC Fulcrum Therapeutics, Inc. | 6,803,785 | $25.2M | 1.24% | Added +4% |
| ORIC ORIC Pharmaceuticals, Inc. | 3,028,116 | $23.3M | 1.15% | Reduced −55% |
| STOK Stoke Therapeutics, Inc. | 835,000 | $22.5M | 1.11% | Added +14% |
| ZBIO Zenas BioPharma, Inc. | 789,500 | $19.8M | 0.97% | Unchanged |
| XNCR Xencor, Inc. | 500,000 | $17.0M | 0.84% | New |
| ADRX ADARx Pharmaceuticals, Inc. | 1,150,000 | $16.3M | 0.80% | New |
| ETRA Electra Therapeutics, Inc. | 1,700,000 | $15.2M | 0.75% | New |
| AURA Aura Biosciences, Inc. | 1,666,667 | $11.6M | 0.57% | Unchanged |
| CAPR Capricor Therapeutics, Inc. | 1,376,580 | $10.4M | 0.51% | New |
| ODTX Odyssey Therapeutics, Inc. | 555,555 | $10.2M | 0.50% | Unchanged |
| ATRA Atara Biotherapeutics, Inc. | 1,552,000 | $9.8M | 0.48% | Unchanged |
| BRVE Braveheart Bio, Inc. | 416,700 | $8.0M | 0.40% | New |
| NRIX Nurix Therapeutics, Inc. | 375,000 | $5.1M | 0.25% | Added +39% |
| ELOX Eloxx Pharmaceuticals, Inc. | 400,000 | $4.3M | 0.21% | Unchanged |
| EIKN Eikon Therapeutics, Inc. | 855,634 | $4.1M | 0.20% | Added +17% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 889,607 | $1.7M | <0.1% | Reduced −68% |
| AARD Aardvark Therapeutics, Inc. | 720,028 | $720K | <0.1% | Added +82% |
| CTNM Contineum Therapeutics, Inc. | 64,303 | $581K | <0.1% | New |